Revenue
8.48 million USD
2020 Q3 · USD
Exact inputs and evidence
- Revenue: 8483030 USD Source
Fundies. English
Enveric Biosciences, Inc.
EDGAR263 filing records in this dataset, filed from 1996-05-14 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-5.77%
2020 Q3 · %
Operating cash flow
-394 thousand USD
2020 Q3 · USD
- Cash and cash equivalents
- 2.84 million USD Source
Exact value
2840097 USD
- Long-term debt including current maturities
- 740 thousand USD Source
Exact value
740336 USD
- Shares outstanding
- 3.94 million shares Source
Exact value
3935884 shares
Reported share-count change
30.07% · 910 thousand shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Capital expenditure
11.4 thousand USD
2022-10-01 – 2023-09-30
Exact inputs and evidence
- Capital expenditure: 584165 USD · 2022-01-01 – 2022-12-31 Source
- Capital expenditure: 577972 USD · 2022-01-01 – 2022-09-30 Source
- Capital expenditure: 5169 USD · 2023-01-01 – 2023-03-31 Source
- Capital expenditure: 5187 USD · 2023-01-01 – 2023-06-30 Source
- Capital expenditure: 5169 USD · 2023-01-01 – 2023-03-31 Source
- Capital expenditure: 5195 USD · 2023-01-01 – 2023-09-30 Source
- Capital expenditure: 5187 USD · 2023-01-01 – 2023-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2019-12-31
- Operating income: 10 of 11 periods available· newest 2025-12-31
- Net income: 10 of 11 periods available· newest 2025-12-31
- Operating cash flow: 10 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2023-12-31
- Total assets: 10 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2022-12-31
- Current assets: 10 of 11 periods available· newest 2025-12-31
- Current liabilities: 10 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2019-12-31
- Long-term debt including current maturities: 3 of 11 periods available· newest 2019-12-31
- Shares outstanding: 10 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+USD 803,000Prior period
−USD 9.57 million
–
Current period
−USD 8.77 million
–
Exact inputs and evidence
-8771987 − -9574987 = 803000 USD
-9574987 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8771987 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 415,404Prior period
−USD 7.73 million
–
Current period
−USD 8.14 million
–
Exact inputs and evidence
-8141543 − -7726139 = -415404 USD
-7726139 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-8141543 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | −USD 814,075 Exact valueExact value: -814075 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 998,177 Exact valueExact value: -998177 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2016 2016-01-01 – 2016-12-31 | −USD 2.78 million Exact valueExact value: -2780686 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.7 million Exact valueExact value: -2703989 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2018-01-01 – 2018-12-31 | −USD 16.9 million Exact valueExact value: -16897516 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.57 million Exact valueExact value: -2565495 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2019-01-01 – 2019-12-31 | −USD 2.41 million Exact valueExact value: -2410673 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 647,860 Exact valueExact value: -647860 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2020-01-01 – 2020-12-31 | −USD 6.86 million Exact valueExact value: -6864676 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.89 million Exact valueExact value: -3888785 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2021-01-01 – 2021-12-31 | −USD 48.98 million Exact valueExact value: -48976896 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.46 million Exact valueExact value: -11457671 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 189,719 Exact valueExact value: 189719 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.65 million Calculation and evidence-11457671 − 189719 USD Exact free cash flow: -11647390 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 18.47 million Exact valueExact value: -18471333 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 17.15 million Exact valueExact value: -17146723 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 584,165 Exact valueExact value: 584165 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 17.73 million Calculation and evidence-17146723 − 584165 USD Exact free cash flow: -17730888 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 17.29 million Exact valueExact value: -17291732 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 14.09 million Exact valueExact value: -14094411 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 5,180 Exact valueExact value: 5180 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 14.1 million Calculation and evidence-14094411 − 5180 USD Exact free cash flow: -14099591 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 9.57 million Exact valueExact value: -9574987 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.73 million Exact valueExact value: -7726139 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −USD 8.77 million Exact valueExact value: -8771987 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 8.14 million Exact valueExact value: -8141543 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
263 filings · 4,132 latest values · 4,132 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000890821, 890821, ENVB, edgar:890821
Also known as AMERI Holdings, Inc., ENVERIC BIOSCIENCES, INC., ENVERIC BIOSCIENCES, INC., Enveric Biosciences, Inc., SPATIALIZER AUDIO LABORATORIES INC